Aurinia Pharmaceuticals - AUPH Stock Forecast, Price & News

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.

7 analysts have issued 12 month price objectives for Aurinia Pharmaceuticals' shares. Their AUPH share price forecasts range from $13.00 to $30.00. On average, they predict the company's stock price to reach $21.20 in the next year. This suggests a possible upside of 156.3% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.

Aurinia Pharmaceuticals' stock was trading at $22.87 on January 1st, 2022. Since then, AUPH shares have decreased by 63.8% and is now trading at $8.27.
View the best growth stocks for 2022 here.

Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our AUPH earnings forecast.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) announced its earnings results on Thursday, August, 4th. The biotechnology company reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.22) by $0.03. Aurinia Pharmaceuticals had a negative net margin of 178.32% and a negative trailing twelve-month return on equity of 38.01%. During the same period last year, the business earned ($0.37) earnings per share.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.21%), HealthInvest Partners AB (0.16%), DnB Asset Management AS (0.10%), Victory Capital Management Inc. (0.07%), Bailard Inc. (0.05%) and Patriot Financial Group Insurance Agency LLC (0.03%). Insiders that own company stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUPH stock can currently be purchased for approximately $8.27.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.17 billion and generates $45.60 million in revenue each year. The biotechnology company earns $-180,970,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis.

Aurinia Pharmaceuticals employs 300 workers across the globe.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.